

02-28-03
GP1631
Express Mail Label No.: EV 139506-440 US
Date of Deposit: February 27, 2003

Attorney Docket No. 15966-599 (Cura 99)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets et al.
SERIAL NUMBER : 09/718,321
EXAMINER : Cheyne D. Ly
FILING DATE : November 22, 2000
ART UNIT : 1631
FOR : NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE POLYMORPHISMS AND METHODS OF USE THEREOF

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 04 2003

TECH CENTER 1800/2000

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Response and Amendment (3 pgs.); and
2. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Although we believe that no fees are due with this submission, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311 (Reference No. 15966-599 (CURA-99)). A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,




30623

PATENT TRADEMARK OFFICE

Ivor R. Elrifi, Reg. No. 48,593
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o Mintz, Levin
One Financial Center
Boston, MA 02111
Telephone (617) 542 6000
Fax (617) 542 2241

Dated: February 27, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets et al.
SERIAL NUMBER : 09/718,321 EXAMINER : Cheyne D. Ly
FILING DATE : November 22, 2000 ART UNIT : 1631
FOR : NUCLEIC ACIDS CONTAINING SINGLE NUCLEOTIDE POLYMORPHISMS AND
METHODS OF USE THEREOF

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 04 2003

RESPONSE AND AMENDMENT

TECH CENTER 1600/2900

This paper is in response to the January 27, 2003 Office Action. These documents are timely filed on or before February 27, 2003. Applicants believe that no additional fees are due. However, the Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-599 (Cura 99).

AMENDMENT UNDER 37 C.F.R. § 1.111

In the Claims:

Please replace the pending claims with the following:

29. (Amended) An isolated polypeptide comprising a polymorphic site at one or more amino acid residues, wherein the protein is encoded by a polymorphic nucleic acid sequence comprising SEQ ID NO:400, or its complement, wherein the nucleotide corresponding to position 26 of SEQ ID NO:400 is not a guanosine.
-
30. (Amended) The isolated polypeptide of claim 29, wherein said polypeptide is translated in the same open reading frame as is a wild type protein whose amino acid sequence is identical to the amino acid sequence of the polymorphic protein except at the site of the polymorphism.
31. (Amended) The isolated polypeptide of claim 29, wherein the polymorphic sequence has an adenosine at position 26.